<DOC>
	<DOC>NCT00362024</DOC>
	<brief_summary>MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.</brief_summary>
	<brief_title>MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male or females Age &gt;/= 55 years, With mildtomoderate AD, with MMSE between 18 and 26, inclusive, MHIS score &lt;/= 4, Global CDR score of 1 or 2 Who have a reliable informant/caregiver to accompany patient to all clinic visits If using a symptomatic AD treatments, patients must be on stable dose for &gt;/= 6 months Patients must not be living in nursing home or skilled nursing facility Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis Patients must not have current evidence and/or history of poorlycontrolled hypertension, clinically significant cardiac arrhythmia, angina, or CHF Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD) Various concomitant therapy restrictions</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>